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The aim of this study is to evaluate medical expenditures and lost productivity associated 
with burden of Salmonella infections. We used laboratory confirmed number of 
Salmonella cases and corresponding multipliers to estimate the burden of illness using the 
method adopted by Foodborne Diseases Active Surveillance Network (FoodNet) at 
Centers for Disease Control and Prevention (CDC). The medical costs estimates are 
retrospective analysis of reimbursement records from MarketScan data. We identified 
patients with a diagnosis of salmonellosis using ICD-9 CM codes from the MarketScan 
1993–2001 databases.  Productivity loss from the nonfatal cases of Salmonella was 
calculated using the distributions of lost workdays and household services due to the 
illness.  Statistical value of life approach was used to estimate the costs due to premature 
deaths.  We also compared the costs for the gastrointestinal salmonellosis to the cost for 
the invasive salmonellosis. Confidence intervals around the cost estimates were 
calculated using a Monte Carlo simulation technique. Estimated average economic 
burden due to Salmonella was $210 per outpatient, $5,797 per inpatient with 
gastrointestinal infection, $16,441 per inpatient with invasive infection and $4.63 million 
per premature death. Total economic burden due to Salmonella in the United States was 
estimated at $2.8 billion (95% CI: $1.6 to  $5.3 billion) annually, which is approximately 
$2,472 per case of Salmonella infection. The cost estimate is largely driven by the 
number of premature deaths followed by average cost of hospitalization. Defining the 
risk factors for fatal outcomes may help target treatment and preventive strategies.  
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Introduction 
Although U.S. food supply has high level of safety, illnesses from foodborne pathogens 
cause billions of dollar loss to the society in terms of medical costs and productivity loss.  
It has been estimated that foodborne illnesses caused by known and unknown pathogens 
result approximately 76 million illnesses, 325,000 hospitalizations, and 5,000 deaths in 
the United States every year (Mead, 1999).  Among several foodborne illnesses, 
salmonellosis is a major illness caused by consumption of Salmonella contaminated 
foods. The infection sometimes spreads from the intestines to the blood stream, and then 
to other body parts.  The disease causes significant burden of illness in the form of 
morbidity and mortality. Infected person may need to seek medical care and visit 
physicians. In severe cases patients are hospitalized and some patients may die 
prematurely due to complications.  Generally the elderly, the infants and the immune 
compromised individuals are affected severely by the Salmonella (Frenzen, et al., 1999).  
An estimated 1.4 million cases of salmonellosis occur every year in the United States.  
Salmonellosis imposes a large economic burden on individual and the society. It has also 
been estimated that approximately 16,000 salmonellosis patients are hospitalized and 600 
persons die each year due to Salmonella infection related diseases
 (Mead, 1999).  
Human salmonellosis associated costs include costs incurred by the person becoming ill 
or by the parties on behalf of the ill person. Direct costs are measured in dollar amount, 
which include medical costs and lost productivity. Cohen et al. 1978 assessed the patient 
related economic costs in an outbreak of salmonellosis in 1976.  According to the study, 
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Direct medical costs and lost productivity were accounted in the study. In an average cost 
incurred by an individual was $645 of which 68 percent was in medical cost, 26 percent 
in productivity loss and 6 percent in miscellaneous costs.  In 1985, indirect cost of single 
episode of non-complicated gastroenteritis was estimated at $215 if the ill person did not 
visit physicians and the cost was $348 if visited physicians (Garthright, et al., 1988). 
Roberts, 1987 updated medical costs and productivity loss using various price indices 
from Bureau of Labor Statistics and also estimated the average value of lost life using 
Landefeld and Seskin (1982) method (Roberts, 1988). Landfield and Seskin method 
includes financial losses due to death but excludes costs associated with leisure time and 
pain and suffering. Frenzen et al, 1999 estimated the economic burden of Salmonella 
infections in the United States and the annual cost estimates ranged from $0.5 to $2.3 
billion depending on the method used (human capital approach and labor market 
approach) to assign value to the human lives (Frenzen, et al., 1999). Center for Food 
Safety and Applied Nutrition (CFSAN) used labor market approach to estimate the 
economic value of lost lives. CFSAN used about $5 million per lost life to assess the 
economic burden of diseases. In addition to medical costs and productivity loss, CFSAN 
also took account of losses due to pain and suffering in cost estimates (Raybourne et al.).  
The economic impacts of salmonellosis from different studies are hard to compare since 
estimates are from different time periods, geographic regions and methods.  Furthermore, 
in most of the studies, there exist great deal of uncertainty surrounding the estimates of 
total number of illnesses, proportions of cases by the severity groups of the disease and 
the average costs of medical care and productivity loss. In general, medical care data are 
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estimates biased and inefficient. Providing the costs estimates along with the underlying 
probability distributions give better picture of economic burden of illness.    
Methods: 
The economic burden estimated in this study includes medical costs, lost productivity 
incurred by the Salmonella infected individuals, and value of lost lives resulting from 
premature deaths. Data were obtained from various sources as listed in table 1. These 
data provide information on the distributions of disease incidence and costs of medical 
care.  Total number of cases is estimated from using laboratory conformed cases and 
multipliers obtained from disease surveillance system.  
Table 1: The data and their sources  
Data Sources 
Distributions of Salmonella cases: 
Self-care, Outpatients, Inpatients 
and Deaths 
1.FoodNet publication (Voetsch et al., 2004)* 
2.Foodborne Diseases Survillance Network 
3.Public Health Laboratory Information System 
Medical Costs: Outpatients costs, 
Inpatient costs, Prescription drugs 
costs 
MarketScan Databases from 1993 to 2001 
(Inpatient Admission, Outpatient Claims and 
Prescription Drugs)** 
Lost Productivity: Work days 
lost, wages, employments 
1. MarketScan Databases from 1993 to 2001 
2. Economic Research Service (ERS) 
3. Bureau of labor statistics 
Value of life  Economic Research Service, USDA 
*Published in Clinical Infectious Diseases (CID) Vol. 38 (3) 
**MarketScan database contains medical care claims reimbursement records for the 
medical services and prescription drugs. Prescription drugs data were not available from 
1993 to 1996 MarketScan database. 
 
Total number of Salmonella cases may vary by year. There are several factors that 
determine the number of cases and existing practices of collecting data have high 
potentials for introducing errors. In order to deal with uncertainty on estimates it would 
be more useful to give the distributions of burden estimates.   
  5Table 2: Reported laboratory confirmed cases and multipliers to estimate the total 
burden of Salmonella  
 
Distributions of multipliers  
Bloody diarrhea 
 (30% to 70% of total) 
Non-bloody diarrhea 




Min Mean Max  Min  Mean Max 
Labs identify Salmonella 1.1 1.4  1.43  1.1 1.4 1.43 
Physicians obtain specimens  1.0  1.0  1.43  3.33  5.5  10 
Patients seek medical care  3.33  6.8  10.0  6.66  8.6  20 
Adapted from Voetsch et al, 2004, “FoodNet Estimate of the Burden of Illness Caused by 
Nontyphoidal Salmonella Infections in the United States”. 
 
Cost of medical care is another important information required to estimate the economic 
impact of a disease. In this study, costs of medical services and prescription drugs data 
were extracted from the MarketScan database. MarketScan database contains 
retrospective medical care claim data maintained by the MedStat Group at Ann Arbor, 
Michigan. We used 1993 to 2001 MarketScan database.  Data consisting of inpatient 
admissions (1993 to 2001), outpatient claims (1993-2001) and prescription drug claims 
(1997 to 2001) from MarketScan database were utilized to estimate the costs.  All the 
claim records marked identified Salmonella as one of the diagnosis codes were isolated 
from the database using ICD-9 CM codes.  In these extracted medical records, 
Salmonella infections were listed either as primary diagnosis or as the secondary 
diagnosis.  Illnesses were categorized into two groups depending on the type of the 
diagnosis code of infections: gastrointestinal infections (ICD 9 CM Codes: 003.0) and 
invasive infections (ICD 9 CM Codes: 003.1, 003.21, 003.22, 003.23, 003.24, 003.29).   
The grouping is done to analyze the variation in treatment costs for invasive Salmonella 
and the gastrointestinal Salmonella.  Outpatient costs and inpatient cost for invasive and 
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Salmonella infections.  The cost due to productivity loss was calculated on the basis of 
workdays and household services lost due to illnesses. National employment rates, wage 
distribution and statistical value of lost lives were taken into consideration while 
estimating the productivity loss.  
Burden of illness: 
CDC reports laboratory confirmed total numbers of salmonellosis cases annually 
(Appendix A) using data reported through disease outbreaks, passive surveillance 
systems: national notifiable diseases surveillance system and public health laboratory 
information system, and active surveillance system: foodborne diseases active 
surveillance system. Medical care multiplier, physician multiplier, laboratory multiplier 
and proportion of bloody and non-bloody diarrhea were used to estimate the total number 
of salmonellosis cases in US based on the laboratory confirmed salmonella cases reported 
to the CDC.  A recent publication by Voetsch et al 2004: "FoodNet estimate of the 
burden of illness caused by nontyphoidal Salmonella infections in the United States" in 
the journal of Clinical Infectious Disease, discusses the method used and results on 
burden estimates.   
The burden of salmonellosis causes significant morbidity and mortality in the United 
States. Severity of the disease is an important aspect of burden of illness. Persons with 
mild salmonellosis did not seek physician or emergency department care for their illness. 
Persons with moderate illness visited at least one physician but were not hospitalized. 
Persons with severe illness were hospitalized at least once during this period. Centers for 
Disease Control and Prevention regularly conduct active surveillance for several 
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data, CDC makes the national estimates of total cases of salmonellosis along with 
proportion of disease outcomes.  In the surveillance system, most culture confirmed cases 
of Salmonella infection are reported to health official. However, there exist strong 
possibility of under reporting.   Persons infected with Salmonella may not develop 
symptoms that require medical attention.  Sometime physician may not collect specimen 
for laboratory tests. Similarly the entire specimen forwarded for laboratory testing may 
not be tested or may not be identified correctly.  It has been estimated that 30,000 to 
40,000 cultures confirmed cases of non-typhoidal Salmonella represent only one percent 
to five percent of the actual number of Salmonella cases in the U.S. population (Chalker, 
1988).  Different multipliers to estimate the total number of Salmonella cases as 
described in appendix A are listed in table 1. Applying these multipliers it has been 
estimated that average annual number of Salmonella cases in U.S. population are 38.6 
times of the culture confirmed cases (Voetsch, 2004).  
Economic burden of salmonellosis: 
Cost of illness is an estimate of direct medical costs associated with treatment of 
salmonellosis and the indirect cost of lost time or wages that may be incurred by either a 
patient or by an unpaid caregiver.  Cost elements include physician visits, hospitalization, 
and prescription drugs. We recognize that the costs of pain and suffering might be 
substantial.  The monetary value of pain and suffering are difficult to estimate with 
accuracy (United States Environmental Protection Agency, 2003) and the direct medical 
costs of treating diseases provides a lower-bound estimate of the cost of illness.  Costs 
per patient represent average expenditure incurred by a patient for one episode of 
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inflation by using medical component of consumer price index.  We categorized 
salmonellosis cases as mild, moderate, and severe by type of medical care sought during 
the illness.  Costs of hospitalization are generally higher if the salmonella infections are 
invasive (blood stream infection) compared to the gastrointestinal infections (non blood 
stream infection). We analyzed the costs of hospitalization for invasive infections and 
gastrointestinal infections separately. 
Medical costs: 
We categorized illness from mild to severe depending on the type of medical care sought 
by the patients. Medical costs for persons treated as outpatients include fees paid for 
ambulance, emergency room services, physician charges and laboratory tests. Inpatient 
costs include fees paid to hospital, physician, and the prescription drugs expenditures 
incurred for the patients who were hospitalized.   
Productivity loss: 
Productivity loss is the income forgone because of illness.  The human-capital approach 
was used to estimate the productivity loss for the nonfatal cases of salmonellosis. Various 
factors such as employment rates, wages, and numbers of workdays lost were used to 
estimate the lost productivity.  Non-wage activities: house keeping, childcare, and other 
activities were also taken into account. Data on length of hospitalization were obtained 
from the MarketScan database (1993 to 2001 inpatient admissions tables).  Since there 
were no reliable data on the lost workdays for outpatients and inpatients after hospital 
discharge, we adopted the assumptions made by ERS in similar studies.  According to the 
Occupational Employment Statistics Survey data from the Bureau of Labor Statistics, 
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wages, ill person is not able to perform household services. Average value of household 
services in US was estimated as much as $10,805 per person annually (Haddix, et. al, 
2000). Adjusting for inflation, average value of household services becomes $30.45 per 
day per patient. 
Value of lost lives:  
Economic burden that Salmonella places to the society also comes from disease 
mortality.  Although it is small, there is a risk of dieing from salmonellosis related 
complications. It is hard to place a dollar value on the lost human lives.  Willingness to 
pay for mortality risk reductions (statistical value of life) is one of the standard 
approaches to estimate the value of lost lives.  Suppose a new hypothetical food safety 
intervention reduces the annual risk of dying of a Salmonella infection by 0.0001.  In a 
community of 10,000 people the intervention is expected to result in 1 fewer death from 
Salmonella infection each year. Using this reasoning, if each person in that population of 
10,000 is willing to pay $20 a year for reducing the risk, the statistical value of a life is 
present value of stream of cash flow of $20,000 per year for the reminder of the life.  
Value of lost lives depends on the age distribution of patients who died of salmonellosis 
related complications. Discount rates used to estimate the present value of future incomes 
also influence the value of life. 
 
Results and discussion: 
Patients with milder illnesses do not visit physicians and they may purchase over the 
counter medications and do not go to the work for certain period of time.  There are no 
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therefore we estimated only the lost productivity for this severity group. Average 
productivity loss for was $53 under the assumptions that the persons with mild illness 
lose only about 0.5 day of work and household services.  
Outpatient costs:  Average medical costs for patients of gastrointestinal and invasive 
Salmonella infections are given in table 3 to compare the average per patient (outpatient) 
costs.  Difference in average outpatient costs for invasive and gastrointestinal infection is 
not statistically significant. Outpatient costs due to the Salmonella infection may reach as 
high as $16,000.  
Table 3: Outpatient costs by types of infections (MarketScan 1993-2001) 
Salmonella type  N  Mean  Std. Dev 25 percentile Median 75 Percentile
Invasive 392  294.55 697.54  56.68  106.26  229.38 
Gastrointestinal 2,596 299.04 742.58  54.12  98.25  221.27 
All Cases  2,988  298.46 736.69  54.45  99.29  222.68 
N=Number of unique cases of Salmonella recorded in MarketScan data 
The range of cost is wide and most of the observations are clustered to the lower end of 
the distribution. The overall mean cost of medications per episode of illness was $298.  
Median cost ($99) was substantially lower than the mean costs, suggesting that 
distribution of outpatient costs was skewed toward right. Fewer salmonella cases were 
driving the mean cost higher. Patients with invasive Salmonella and gastrointestinal 
Salmonella had the mean costs: $295 and $299 respectively.   Statistical analysis 
indicated that the differences in costs of medications between the types of infection were 
not significant (Table 4).  We assumed that outpatients are not able to perform their 
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household services were estimated as $169 per outpatient.   
Inpatient costs:  Overall mean direct medical cost of hospitalization per case of 
salmonellosis was $7,734.  Median cost ($4,789) was substantially lower than the mean 
costs.  Hospitalized patients who were diagnosed with invasive Salmonella and 
gastrointestinal Salmonella had the mean costs of $16,215 and $5,981 respectively (table 
4).    
Table 4: Average inpatient costs by type of infections (MarketScan 1993-2001) 
Salmonella type  N  Mean  Std. Dev 25 percentile Median 75 Percentile 
Invasive 136  16,215  23,222  5,576  9,466  16,200 
Gastrointestinal 657 5,981  8,222  2,820  4,385  6,381 
All Cases  793  7,734  12,760  2,990  4,789  7,502 
N=Number of unique cases of Salmonella recorded in MarketScan data 
Statistical analysis indicated that the difference in costs of hospitalization between the 
types of infection was significant.  Inpatients cost per episode of Salmonella related 
hospitalization ranges from $240-149,087. The range is wide and most of the 
observations are concentrated to the lower range in the distribution.  Standard deviations 
are high.  Few influential data points made the range wider and larger standard deviation.  
Average costs difference by type of infection are statistically significant at 0.01 
probability level.  In general, mean or the median medical costs are higher for the 
invasive infection, compared with gastrointestinal infections. According to the 
MarketScan data average lengths of hospitalizations were 8.9 days and 4.2 days for 
invasive and gastrointestinal infections respectively.  We assumed that patients are not 
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for about 1.6 days in average. After taking account of distribution of US wages, 
employment rates, five working days per week and lost household services, average 
productivity losses among hospitalized patients were $1,110 and $604 per episode of 
invasive and gastrointestinal infections respectively. 
Costs of fatal cases: Value of lost lives was treated as an annuity. In 1990, USDA 
Economic Research Service assumed the present value of the annuity at the age of 36.5 
years as much as $5,000,000, as estimated by Kip Viscusi from labor market data. After 
adjusting for inflation, the value of life becomes $6,618,087 in 2001 dollars. Under the 
assumptions of constant annual value of life, 3% discount rate, underlying age 
distribution of Salmonella related deaths (multiple causes of death certificates) and life 
expectancy; average estimated value of lost lives was $4,624,171 in 2001dollar value. 
Monte Carlo Simulation: 
Most of the estimates on variables used in the cost analysis have uncertainty. 
Expected or the average values do not show the impact of uncertainty. Therefore, the 
point estimates may not give the decision-maker a complete picture of possible burden of 
illness and its economic consequences.  A Probability distribution of relative occurrence 
for each possible outcome gives the better information than the traditional descriptive 
analysis. Ranges of burden of illness and associated costs directly related to the level of 
underlying uncertainly in the variables involved in the estimates. Distributions of health 
care costs associated with Salmonella infections are not normal and skewed with large 
positive tail. Analyzing the costs entering the distributions of variables show all the 
possible outcomes with relative frequencies/probabilities.  
  13Estimation of location and variation parameters of distribution is an important 
task in data analysis. The simulation results are given in appendix B and appendix C. 
Most of the fitted distributions of disease outcomes have zero skewness indicating that 
simulated data are normal. Distributions of medical care costs have positive coefficients, 
which imply that distributions have long tails to the right. Positive skewness of health 
care cost is a normal phenomenon.  Inpatient and outpatient costs summarized in 
Appendix B (simulated cost data) are somewhat different than the cost extracted from 
MarketScan database listed in table 3.  Total economic burden due to Salmonella are 
calculated by the Monte Carlo Simulation method instead of simply multiplying the total 
number of cases by the average costs.  Estimated annual economic burden (medical costs 
and productivity loss) of salmonellosis is about $2.8 billion (95 % CI: $1.6 to $5.3 
billion). Fig. 2 and fig. 3 show the relative frequency of distributions of economic burden.   
Distribution of costs is dramatically affected by the method used to value the lost human 
lives. If the lives were valued by the human capital approach then the estimated mean 
economic burden would be about $453 million. 
Conclusion:   
Salmonellosis is a major foodborne illness caused by consumption of Salmonella 
contaminated foods. Epidemiological estimates of burden of Salmonella infection have 
been revisited. Medical costs and productivity loss by the severity of illness have also 
been estimated to translate the burden of illness into the economic burden by calculating 
societal costs which include direct healthcare expenditures and productivity losses.  The 
medical costs estimates are retrospective analysis of reimbursement records from 
MarketScan data.  Confidence intervals around the cost estimates were calculated using a 
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average medical expenditure and productivity loss due to Salmonella was $210 per 
outpatient, $5,797 per inpatient with gastrointestinal infection, $16,441 per inpatient with 
invasive infection. Total economic burden due to Salmonella in the United States was 
estimated at $2.8 billion (95% CI: $1.6 to  $5.3 billion) annually.  However, if lost lives 
were valued by the human capital approach the average costs would be dramatically 
lower. Total cost estimate is driven by premature deaths followed by cost of 
hospitalization.  
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  17Appendix A: Distribution of Salmonella related illness and disease outcomes (1990-
2001) 












1991  40,443 1,436,618  1,271,099 144,333 3,530 17,051 606 
1992  34,688 1,232,188  1,090,222 123,794 3,027 14,625 519 
1993  36,917 1,311,367  1,160,279 131,749 3,222 15,565 553 
1994  37,522 1,332,858  1,179,293 133,908 3,275 15,820 562 
1995  41,222 1,464,289  1,295,582 147,113 3,598 17,380 617 
1996  39,035 1,386,603  1,226,846 139,308 3,407 16,458 584 
1997  34,608 1,229,347  1,087,708 123,509 3,020 14,591 518 
1998  33,971 1,206,719  1,067,688 121,236 2,965 14,323 509 
1999  32,782 1,164,483  1,030,318 116,992 2,861 13,821 491 
2000  33,310 1,183,239  1,046,913 118,877 2,907 14,044 499 
2001  31,675 1,125,161  995,526  113,042 2,764 13,355 474 
Average  36,016  1,289,567  1,140,990 129,559 3,168 15,306 544 
*Estimated based on the laboratory confirmed cases, laboratory multipliers, Physician 
multipliers, medical care multipliers. 
**Adopted from Mead et al. (1997).  
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Statistics 
Total Burden  
(Per year) 
Expected burden
($ Per case) 
Total Salmonella Outpatient
(Cases per year)
 Inpatient cost $ 
Cost $  (Invasive)  
Inpatient cost $
(GI)* 
Minimum 2,300,435,000  1,789  567,738  0  486  415 
Maximum 6,241,845,000  5,788  4,237,218  21,377  511,898  146,971 
Mean 2,788,166,000  2,472  1,395,387  211 16,441  5,796 
Std Deviation  304,935,200  361  460,865  715  27,232  6,370 
Skewness 1  1  1  17  8  9 
Kurtosis 13  7  6 434  116 150 
Mode 2,605,684,000  2,307  1,253,904 27  5,060  3,468 
5 Percentile   2,380,997,000  1,930  833,274  13  2,341  1,539 
10 Percentile 2,421,065,000  2,004  907,987  20  3,146  1,954 
25 Percentile 2,526,077,000  2,215  1,061,917  38  5,111  2,889 
50 Percentile 2,779,571,000  2,439  1,305,938  79  9,264  4,336 
75 Percentile 3,013,454,000  2,721  1,625,152  174  17,502  6,716 
80 Percentile 3,041,384,000  2,792  1,718,037  214  20,644  7,462 
90 Percentile 3,123,256,000  2,965  1,989,777  390  33,388  10,229 
95 Percentile 3,210,036,000  3,056  2,245,501  679  51,776  13,924 
*GI=Gastrointestinal Salmonella infection 







Inpatients  No. of Deaths (Invasive)*
LOS Days  LOS Days 
(Non-invasive)
Minimum 995,526  113,042  2,764  13,355  474  0  0 
Maximum 1,295,582  147,113 3,598  17,380  617  109  33 
Mean 1,138,840  129,646  3,171  15,297  543  9  4 
Std Deviation  113,448  12,975  316  1,517  54  10  3 
Skewness 0  0 0  0  0  3  3 
Kurtosis 1 1  1  1  1 19 18 
Mode 995,526  113,042  2,764  13,355  474 2  2 
5 Percentile  995,852  113,078  2,765  13,359  474  1  1 
10 Percentile  997,476  113,267  2,770  13,387  475  2  2 
25 Percentile  1,019,070  115,913  2,837  13,715  486  3  2 
50 Percentile  1,130,490  129,172  3,153  15,215  539  6  3 
75 Percentile  1,259,128  143,456  3,505  16,904  600  11  5 
80 Percentile  1,274,848  145,070  3,546  17,099  607  13  6 
90 Percentile  1,292,032  146,783  3,589  17,333  615  20  7 
95 Percentile  1,295,019  147,061  3,596  17,372  617  27  10 
*LOS=Length of hospital stay in days
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Fig 2: Economic burden due to Salmonella in U.S. (human capital approach) 




Fig 3: Economic burden due to Salmonella in U.S. (labor market approach) 
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